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Abstract Several studies have provided ample evidence
of a clinically significant interobserver variation of the
histological diagnosis of glioma. This interobserver varia-
tion has an effect on both the typing and grading of glial
tumors. Since treatment decisions are based on histological
diagnosis and grading, this affects patient care: erroneous
classification and grading may result in both over- and
undertreatment. In particular, the radiotherapy dosage
and the use of chemotherapy are affected by tumor grade
and lineage. It also affects the conduct and interpretation of
clinical trials on glioma, in particular of studies into grade
II and grade III gliomas. Although trials with central
pathology review prior to inclusion will result in a more
homogeneous patient population, the interpretation and
external validity of such trials are still affected by this, and
the question whether results of such trials can be general-
ized to patients diagnosed and treated elsewhere remains to
be answered. Although molecular classification may help
in typing and grading tumors, as of today this is still in its
infancy and unlikely to completely replace histological
classification. Routine pathology review in everyday clin-
ical practice should be considered. More objective
histological criteria for the grade and lineage of gliomas
are urgently needed.
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A case report illustrating the problem
In May 2008, the principal investigator of an EORTC study
on anaplastic glioma (CATNON) was contacted by the
local investigator of one of the participating institutions. A
brain tumor patient operated and diagnosed in a third
institution as anaplastic astrocytoma (AA) (Fig. 1a–d) was
referred for further treatment, and the local investigator
was considering to enter the patient in the CATNON study.
However, his own pathologist had diagnosed a low grade
astrocytoma. The local investigator asked how this patient
should be treated, and if he was eligible for the study or
whether he should be entered in another study on low grade
glioma. It was decided to submit the tumor material for
central pathology review that is part of the CATNON
study. This study requires confirmation of the pathological
diagnosis by either one of two independent pathologists.
The diagnosis of the first central review pathologist for the
CATNON study was AA, and because of this the patient
was eligible. However, the second central pathologist of
the CATNON study felt that this tumor was a low grade
astrocytoma. Because confirmation by one pathologist
suffices for inclusion in the CATNON study, after the
required 1p/19q testing the patient was randomized into
this study.
Several issues that potentially influenced the diagnosis
were identified in this case: (a) the specimen was of a
relatively poor quality (Fig. 1a); (b) the number of mitoses
that are acceptable for grade II is unclear (Fig. 1b); (c)
some ‘‘incipient’’ microvascular proliferation was observed
(Fig. 1c; true microvascular proliferation would grade the
tumor as GBM); (d) there are gemistocytes (the accept-
ability of a substantial number of gemistocytes for grade II
is disputed, although in the official WHO 2007 book
gemistocytic astrocytoma is still considered grade II
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(Fig. 1d). Based on these different diagnoses, the patient
could have been treated with either 50 or 60 Gy radio-
therapy, and could have been entered in two different
studies which ask different questions and which employ
different (standard) treatment regimens. If he would have
been suffering from a low grade tumor that was treated as a
high grade tumor, he would be overtreated, if the opposite
was true he would be undertreated. The absence of
objective external validation makes this problem compa-
rable to the baron of Mu¨nchhausen, dragging himself at his
tuft out of a marsh (Table 1).
Introduction
A number of studies have firmly established the presence
and clinical relevance of interobserver variation in the
pathological diagnosis of glioma. In a systematic series on
a cohort of 500 brain tumor patients routinely reviewed as a
part of daily patient care, some degree of disagreement was
present in 42.8%, which was considered serious in 8.8%
[2]. Aldape et al. [1] noted discordant diagnoses in 23% of
457 cases referred for the San Francisco Adult Glioma
Study, with higher degrees of discordance in cases referred
by local community hospitals as opposed to academic
hospitals. 16% of the discordant diagnoses were considered
to be clinically significant, altering patient management
and/or prognosis. In a prospective study on 244 cases
reviewed by 4 pathologists, Coons et al. [9] showed that
diagnostic concordance can be improved by a repetition of
the review process. The four reviewers agreed in only 52%
of cases in the initial review, but in 69% of cases after the
fourth review. The authors concluded that much of the
improvement was related to the refinement of criteria dis-
tinguishing diffuse astrocytomas from oligodendrogliomas/
oligoastrocytomas and pilocytic astrocytomas, representing
distinctions which are clinically quite relevant. This study
also suggested that oligodendrogliomas comprised about
25% of all gliomas, although initially only 5% had been
diagnosed as oligodendroglioma. This report exemplifies
the temporary increase in percentage of diffuse gliomas
diagnosed as oligodendroglial in the late 1990s. This trend
was reversed only once it became clear that more classical
features correlated with the presence of the combined 1p/
19q co-deletion associated with increased sensitivity to
chemotherapy [3, 16, 21, 27, 30, 36]. One of these studies
on the presence of 1p/19q co-deletion in diffuse glioma
which reviewed 162 cases noted unanimous agreement
among three pathologists for histologic subtype classifica-
tion in 69% (36 of 52) of oligodendrogliomas, 13% (4 of
31) of mixed oligoastrocytomas, and 76% (60 of 79) of
astrocytomas [30]. Several studies more specifically
investigated the diagnosis of oligodendroglial tumors. A
series of 124 cases of low and high grade oligodendrogli-
oma was used to establish the reproducibility of
histological grading criteria between 13 pathologists [12].
Reproducibility appeared to be moderate (j score
0.41–0.60) or substantial (0.61–0.80) for only some fea-
tures upon which the WHO grading system is based. These
authors also noted that a preliminary written explanation
Fig. 1 A case submitted for
inclusion in the CATNON study
on anaplastic glioma without
1p/19q co-deletion, showing
a overall relatively poor quality
with stretched and discohesive
material; b a sporadic mitosis;
c ‘‘incipient’’ microvascular
proliferation; and
d gemistocytic cells including
one with mitosis
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appeared to increase the reproducibility of some of
the items, in particular the presence of high cellularity, the
presence of mitosis, the number of mitoses per ten HPF, the
presence of microcalcifications, endothelial hypertrophy
and proliferation and necrosis. For the overall diagnosis of
anaplasia, the j score was well below 0.40. A panel review
on 131 tumors showed that in 83% of cases 4 out of 5
pathologists reached consensus on the diagnosis of classi-
cal oligodendroglial features [21].
As a conclusion, it seems safe to assume that 20–30% of
gliomas are reclassified when the tumor material is inde-
pendently reviewed. These difficulties in the diagnosis of
brain tumors are not to be understood as simple mistakes.
The way in which the diagnostic classes of gliomas are
described leaves room for subjective interpretation and
other variations, as further discussed below. Moreover, the
histopathological criteria have changed over time. In
the 1990s, the presence of endothelial proliferation even in
the absence of necrosis in astrocytic tumors became suffi-
cient to classify these tumors as glioblastoma (GBM).
More recently, the presence of necrosis in mixed anaplastic
oligoastrocytoma (AOA) became in the WHO 2007 suffi-
cient to classify these tumors as GBM or as glioblastoma
with oligodendroglial differentiation (GBM-O) [24, 37].
Both are examples of rather defined changes, described in
detail in the WHO classification, although it still leaves
room for interpretation (what distinguishes a pure ana-
plastic oligodendroglioma with necrosis from a mixed
AOA with necrosis? How is endothelial proliferation
defined?). The studies of Coons et al. that noted oligo-
dendroglioma represent 20–25% of all gliomas present a
more difficult and apparently more subjective issue. Of
relevance, the authors noted that classical histological
features of oligodendroglioma were not required for its
diagnosis: the presence of a mucopolysaccharide-rich
extracellular fluid, prominent perineuronal satellitosis or
extensive grey matter involvement and microcalcifications
were considered supportive of a diagnosis of oligoden-
droglioma. Here, an unspecified change occurred
simultaneously with the clinical desire to diagnose oligo-
dendrogliomas because of their chemosensitivity [4, 9, 35].
This shift was followed by a rebounce tightening of criteria
which occurred once that non-histological data (1p/19q
deletion) showed that the widening histological criteria
diluted the percentage of chemo-sensitive tumors [3, 27].
Here, external—molecular—criteria guided a gradual
change in histological criteria.
Pathology review within clinical trials
With the knowledge of the significant interobserver varia-
tion, the question of how this affects the conduct and
interpretation of prospective randomized clinical trials is
highly relevant and all too often ignored. One of the first
attempts to explore the role of pathology review within a
prospective clinical trial on high grade glioma was done
within an RTOG study [28]. This study noted a high degree
of concordance in locally diagnosed GBM cases (96%), but
in only 66% of astrocytomas with anaplastic foci (AAF).
Locally diagnosed AAF that were reclassified as GBM had
a GBM like survival, whereas locally diagnosed GBM
cases that were reclassified as AAF had an in-between
survival. This is noteworthy, as apparently the initial local
diagnosis of a GBM did make a difference in outcome. It
suggests that the initial diagnosis of AAF picked out a
subgroup that had a better outcome, despite the central
review diagnosis of GBM. The authors showed that the
misclassification they observed would seriously affect
the power of a clinical study on AAF, assuming that the
investigational treatment does improve outcome in AAF
but not in GBM. Some confirmation of that assumption
comes from an EORTC study on AA [14]. That study
failed to show an improvement of adjuvant chemotherapy,
but similar to the RTOG study a high level of histological
disconcordance was noted. At central pathology review,
over half (53%) of the locally diagnosed AA cases could
not be confirmed. Of note, a second reviewer disagreed
frequently with the first reviewer but a sensitivity analysis
of the study based on confirmed AA by either of the two
central pathologists showed an improved outcome after
adjuvant chemotherapy compared to treatment with
radiotherapy alone (EORTC, data on file). Similarly, a
large randomized study on grade II glioma confirmed the
presence of a low grade glioma in 74% of patients of whom
material was available for review [33]. Since today’s trials
are focused on specific tumor types and grades, differences
between pathologists have to be addressed in the design
and interpretation of these studies in particular on grade II
and grade III tumors.
Two recent trials have studied the impact of
(neo)adjuvant PCV chemotherapy in anaplastic oligoden-
droglioma (AOD) and AOA. The rationale of both studies
was the observed high response rates to PCV chemotherapy
of recurrent anaplastic oligodendroglial tumors, which was
at the time of study start still understood as related to oli-
godendroglial morphology [4, 35]. This was subsequently
associated with combined 1p/19q loss [6]. For both trials,
both pure and mixed anaplastic oligodendroglial tumors
were eligible, and they required either two or three ana-
plastic features to be present as part of the inclusion criteria
[5, 34]. Mixed tumors were allowed in both trials provided
25% of oligodendroglial elements were present. One
trial—conducted by the RTOG in North America—
required central confirmation of the diagnosis prior to study
inclusion, the other—European—EORTC trial had central
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pathology review after the inclusion. Both trials showed
that (neo)adjuvant PCV improves progression-free survival
but not overall survival. In both trials, results of pathology
review of included patients have been published.
In the EORTC trial on 368 patients, the diagnosis of a
grade III oligodendroglial tumor was confirmed in 257
patients out of 348 with material available for review
(74%) [15]. The EORTC trial has been used to study the
interobserver variation of the pathology diagnosis. Using a
review panel, 114 cases were classified by 9 independent
pathologists [17]. Review diagnoses ranged from low grade
astrocytoma to GBM. The panel reached a consensus on
52% of AOD and in only 8% of the AOA, and survival was
clearly associated with the diagnosis at review. Molecular
analysis in the dataset of the EORTC study demonstrated
combined 1p/19q loss in only 26% of the cases with suf-
ficient material available for analysis, and in considerable
percentages of patients molecular lesions usually associ-
ated with GBM were found (e.g. EGFR amplification in 51
out of 233 samples) [15]. Clearly, this trial suffered from a
more heterogeneous patient population than intended, with
many patients harboring glioblastoma-like tumors and only
a minority of the patients having the chemotherapy sensi-
tivity-associated 1p/19q co-deletion.
A different route was taken in the RTOG trial 94-02.
Here, pathology review was conducted prior to study entry,
although unfortunately it is unclear how many patients
were rejected from the trial because of discordant pathol-
ogy diagnoses at central review. The percentage of patients
with tumor with 1p/19q loss in this study was considerably
higher as compared to the EORTC study (93 of 201 cases;
46%). In this study, a second pathology review study has
been conducted after the first central review to confirm the
patient’s eligibility resulting in an enriched for oligoden-
droglioma patient population. For that study, all available
samples were reviewed by two new and independent
reviewers and in case of disagreement by a third reviewer
[11]. The authors scored the samples for the presence or
absence of ‘‘classical for oligodendroglioma (CFO),
including cellular monomorphism, round/regular nuclei,
presence of nodules, microcalcifications, microcysts, and
chickenwire vasculature’’. CFO tumors were highly asso-
ciated with 1p/19q loss (present in 80%; as opposed to only
13% of non-CFO). The authors concluded that central
pathology review is an important component to establish
uniformity of entry criteria in future trials. Moreover, in
CFO, a trend toward increased survival after neoadjuvant
PCV was present. Nonetheless, the j score between the two
expert pathologists was only 0.55, indicative of a moderate
amount of interobserver agreement. One of the experts did
not classify 25 as CFO out of 115 cases that were con-
sidered CFO at the end of the review process. Moreover,
despite the central pathology review at study entry
confirming the oligodendroglial nature of the tumor (and
thus all cases were diagnosed as oligodendroglioma by two
pathologists), the reviewers that took part in the second
review still diagnosed some tumors as AA or GBM.
A German study on anaplastic glioma (regardless of
lineage) compared initial treatment with chemotherapy
versus initial treatment with radiotherapy [38]. Similar to
the RTOG study, central confirmation of the histological
diagnosis was required prior to study entry. The investi-
gators noted a high concordance between the local and the
central diagnosis (j = 0.7). Remarkably, they also noted a
similar survival in AOA and AOD, in which sense this trial
is unique: virtually all studies on this topic have shown a
better survival in AOD as compared to AOA [11, 15, 22].
This suggests that despite the good concordance the results
may differ from those obtained in other countries. Some
indications what may have played a role here are only
touched upon by the authors in the discussion part of the
manuscript. Here, it is mentioned that a rather restrictive
central histologic AOA classification was used: cases of
astrocytic tumors with just minute or ambiguous oligo-
dendroglial differentiation features did not qualify for the
diagnosis of AOA. It thus appears that the criteria for
mixed oligoastrocytomas were narrowed. In fact, older
studies have already shown the interobserver variation in
the diagnosis of mixed oligoastrocytoma [18]. If the border
between AOA and AA is shifted toward a more oligo-
dendroglial phenotype, stage migration (also known as the
Will Rogers phenomenon) occurs and it is no longer a
surprise the survival of AOA becomes similar to that of
AOD [10]. Indeed, the blunt statement in the abstract that
AOD and AOA share the same better prognosis than AA is
in fact illustrative of the different set of criteria used and
indicative of the role of interobserver variation and of stage
migration.
What is the explanation of the consistent presence
of interobserver variation?
Some of the interobserver variations appear simply due to
technicalities: not reviewing exactly the same material may
result in a different diagnosis because of sample differ-
ences. This may especially be an issue in cases in which
only very tiny fragments or a few slides are submitted for
the review process (sample error). As an example, cases
have been observed where the submission of more material
resulted in a different diagnosis. More fundamental is
however the way tumors are classified. Several subtypes of
glioma exist, which are currently distinguished by their
morphological appearance. The standard for brain tumor
classification, the WHO classification, uses morphological
descriptions for the various histologies and grades which
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contain subjective elements, with terms such as ‘moder-
ately increased’ cellularity for grade II astrocytoma,
and ‘increased cellularity’ for AA [19]. For the outsider,
the descriptions contain elements of circular reasoning:
oligodendroglioma is ‘‘composed of neoplastic cells mor-
phologically resembling oligodendroglia…’’ [25]. Because
of these definitions, boundaries between grades and tumor
types are subject to interpretation, and pathology remains
an art rather than fully evidence-based science. Perhaps
more importantly, the dedifferentiation of low grade
tumors into more high grade tumors is a gradual and
continuous process, and as a result the boundaries between
grades are artificial: tumor grades are not reflecting true
and existing different entities.
Would molecular diagnostics improve the situation?
The current concept behind WHO classification into grade
I–IV tumors is that it reflects overall outcome. The phe-
notype of a tumor is the result of the genotype and the
influence of the tumor’s environment on the tumor. One
would expect that molecular diagnostics will contribute to
a better classification of brain tumors. As an example, a
recent study conducted at our department on 60 patients
with recurrent astrocytoma treated with temozolomide
showed three cases with combined 1p/19q loss (Taal et al.,
submitted). All were confirmed astrocytomas at central
review, all three had a complete response to temozolomide
which is a treatment outcome one would expect in 1p/19q
co-deleted oligodendroglioma. The class of mixed oligo-
astrocytomas is a clear example of the difficulties of glioma
histology. This diagnosis is by definition the result of the
presence of a group of tumors that have both astrocytic and
oligodendroglial elements. It has long been clear however
that at the molecular level these tumors usually show either
1p/19q co-deletion suggestive of an oligodendroglial
tumor, or TP53 mutations suggestive of astrocytic lineage
[20]. The WHO 2007 has dealt to some extent with this
category of mixed tumors, by removing the AOAs with
necrosis from the anaplastic glioma to the grade IV tumors.
That leaves unanswered whether there is any rationale to
label these tumors glioblastoma with oligodendroglial
features, although survival of this group may be slightly
better [15, 21]. However, this remains a mixed bag of
tumors, difficult to sort out with morphological criteria
alone.
Indeed, the results of studies on systemic molecular
analysis are beginning to allow the identification of tumors
at a more fundamental level, and have increased our
understanding of some aspects of the clinical behavior of
these tumors. In particular, 1p/19q loss, TP53 mutations,
IDH1 mutations, EGFR amplification, PTEN mutations are
now believed to characterize specific subsets of tumors,
related to grade and lineage of various glial tumors. The
above-mentioned example showed that astrocytic tumors
with 1p/19q co-deletion may respond similarly to chemo-
therapy as one would expect from oligodendroglial tumors,
providing a rationale for molecular entry criteria as
opposed to histological entry criteria.
If molecular analysis is used for the classification of
glioma, the next question would be which type of molec-
ular analysis would be used for that and whether histology
continues to play a decisive role in that process. In several
studies, it has been shown that molecular classification
based on gene expression analysis provided a more accu-
rate predictor of survival than histology [13, 23, 29]. In one
of these studies on 276 gliomas, molecularly defined
clusters contained a wide variety of histologies and grades,
and vice versa the various histologies and grades ended in
different clusters [13]. Within the GBM, gene expression
arrays allowed the identification of several genes that
correlate with subclasses of GBM with different outcome
and perhaps different outcome to treatment [8]. Although a
molecularly based classification of glioma is an attractive
idea, many questions still remain unanswered. As an
example, the reviewers of RTOG trial noted that histo-
logically defined ‘classical for oligodendroglioma tumors’
may actually benefit from PCV chemotherapy, which could
not be demonstrated for 1p/19q loss. Indeed, clustering
analysis of gene expression analysis of a large set of glioma
showed that several of non-1p/19q co-deleted tumors
clustered with 1p/19q co-deleted tumors and some GBM
clustered with pilocytic tumors [13]. More likely, a com-
bined histological and molecular approach will improve
outcome.
Also, the current WHO classification of brain tumors
and the treatment decisions based on it are the results of
years of clinical research. Any new classification has to
prove itself in a prospective study that demonstrates the
new classification is better correlated with survival and—
preferably—improves the outcome. Such an effort could be
limited to a subset of tumors undergoing a specific treat-
ment: any molecular criterion that predicts outcome of a
subgroup of glioma to a specific treatment would be a
major leap forward. Current large cooperative group trials
are using molecular entry criteria (especially 1p/19q status
and MGMT promoter methylation). Analysis of the
results—and unfortunately the maturation of these trials
may take years—will tell if these entry criteria provide a
step forwards. Of note, before molecular criteria are
accepted, a similar process of assessment of interlaboratory
variation should be conducted. Results from MGMT pro-
moter methylation studies have shown methylation rates
varying from 20 to 66%, most likely resulting from dif-
ferences in laboratories [7, 32]. As long as science is the
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objective of these assays, this is no major concern, but such
differences are intolerable if the assays are used for the
clinical management of patients.
Pathology review and conclusions derived from clinical
trials
Although the conclusion from the above presented data on
interobserver variation appears to be that central pathology
review should be mandatory prior to patient inclusion in
clinical trials on glioma, that does not cover all the aspects
of the problem. Intuitively, it may appear to make sense to
include patients only after central review of the diagnosis
as this will result in a more reliable and homogeneous
population. However, it does not necessarily imply that a
more ‘correct’ population is included. In the absence of a
gold standard, this diagnosis remains an art. It does ensure,
however, a more homogenous patient population, but even
here issues are present. There are very little data on
intraobserver variation, but it seems reasonable to assume
that it will be less than the variation present between dif-
ferent observers. Nonetheless, even after central mandatory
review at baseline of a trial, the problem still exists at the
next level. Should any new treatment result in a better
survival in a specific tumor type or grade as demonstrated
in a clinical trial with central histology confirmation prior
to randomization, it will still be the local pathologists who
assign tumor type and grade to the patient: day to day
clinical decisions on the management of these patients will
continue to be guided by the local pathologists. In other
words, the results of a trial for which patients were only
eligible after central review will only be ‘true’ for the
patients diagnosed with a specific condition by the specific
central pathologists of that study, and cannot be automat-
ically generalized to patients diagnosed with that condition
by other pathologists. This issue is on the question of
external validation or generalizability of the results of a
trial, an often ignored element of clinical trials [26]. That
question addresses whether the results of a trial can be
reasonably applied to a group of patients diagnosed with
that condition in a particular setting in routine clinical
practice. Restrictive inclusion criteria and local policies of
centers participating in a trial that result in only a subset of
patients with a given diagnosis entering a particular trial
limit the external validity of that trial. In the way, the trial
is reported some of these can be addressed, from the
pathology perspective one minimal requirement ought to
be that the number of patients rejected because of non-
confirmed histology is reported [31].
The opposite reasoning is that entering patients into a
trial based on the local diagnosis reflects a more ‘real life
scenario’, or every day’s clinical practice. However, it
needs to be realized that the question whether the conclu-
sion of a trial on a specific subtype can be generalized to all
patients locally diagnosed with that tumor also holds for a
trial in which patients were entered based on the local
diagnosis. After such a trial, any local center will have the
same issues when trying to define its own patients in
comparison to the reported general study population. In
fact, because of the likely increased heterogeneity of
included tumors, the amount of uncertainty about the actual
histologies included in the trial will be larger.
Clinical perspective
For clinicians, it is important to realize the limitations of the
pathological diagnosis of glioma. Most importantly, they
should understand that pathological diagnoses are not
carved in stone and are subject to interobserver variation.
Also, they should realize that glioma grades are not to be
understood as distinct biological entities. That implies that
the clinical information including the scan details should be
considered when making treatment plans, and in case of
issues the opinion of another pathologist should be asked.
For pathologists, it is important to understand that this is not
a motion of non-confidence. On a daily basis, they are taking
decisions which can be traced down for the years to come
which makes their work more difficult and easy to criti-
cize—but that is certainly not the intention of this review.
The psychology of multiple pathologists reviewing
cases is complicated in itself. This should be organized in
a way that this does not become a process of bargaining
and authority. Circulating slides from clinically annotated
cases in order to decrease interobserver variation is
something that should be considered. This should be
organized on an international level, to avoid the devel-
opment of national standards not shared in other
countries. Histology review as part of a clinical trial
brings another issue: what if the central review diagnosis
considers another diagnosis, which would justify another
treatment choice? Or even randomization in another trial?
First, it needs to be realized that the central review
pathologist as a rule will not have a legal status in the
hospital of the treating physician. Then, the central
diagnosis in a particular patient is another opinion, not
necessarily the correct one. The clinician should try to
integrate both opinions into the management of the
patient, using other evidence to guide treatment decisions
(aspects of MR scans, age of the patient and the like). It
may seem a slippery slope, but not having the second
opinion (or even ignoring it) does not make it less slip-
pery. And, patients are entitled to be informed of these
kinds of disagreements. Which is sometimes difficult to
explain, especially if the consequences are big (Table 1).
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Conclusion
Interobserver variation in the pathological diagnosis is a
well-recognized and major issue in both the management
of brain tumor patients and the conduct of clinical trials on
brain tumors. Although in trials mandatory pathology
review at baseline is likely to result in a more homoge-
neous patient population, the absence of objective and
quantitative criteria for the histological diagnosis implies
that even after central review prior to inclusion the entered
patients represent merely a sample taken according to the
diagnosis of one pathologist. This questions the external
validity and generalizability of the trial results. More
objective, quantitative and in particular reproducible his-
tological criteria are urgently needed, as patient treatment,
trial conduct and trial interpretation depend on the adequate
selection of specific treatments for specific patients. If
molecular criteria improve the classification of tumors,
once validated these should be introduced into the WHO
criteria for brain tumors without further delay. Current
trials are using molecular entry criteria, but it will take
years before results become available. Routine review of
the histological diagnosis of glioma by a second patholo-
gist in daily clinical practice should be considered,
preferably from an outside institution. Today’s communi-
cation technologies are beginning to make this feasible
even without the material transfer of tumor specimens.
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